Kieron Dunleavy
Overview
Explore the profile of Kieron Dunleavy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
126
Citations
3456
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Lakhotia R, Melani C, Dunleavy K, Pittaluga S, Desai S, Ahlman M, et al.
Leuk Lymphoma
. 2025 Feb;
:1-12.
PMID: 39899393
Immune cells within the lymphoma tumor microenvironment promote immune evasion and are rational therapeutic targets. Alemtuzumab targets CD52 expressed on malignant B-cells and infiltrating nonmalignant T-cells. We evaluated the safety...
3.
Gupta N, Carsons S, Carteron N, Scofield R, Lee A, Thomas D, et al.
Arthritis Care Res (Hoboken)
. 2024 Nov;
PMID: 39605233
No abstract available.
4.
Alig S, Chapuy B, Ennishi D, Dunleavy K, Hodson D
Histopathology
. 2024 Nov;
86(1):94-105.
PMID: 39545339
This review aims to provide an overview of the latest developments in the classification and molecular understanding of aggressive B-cell lymphomas, specifically focusing on diffuse large B-cell lymphoma (DLBCL) and...
5.
Campo E, Dierickx D, Dirnhofer S, Dunleavy K, Gaulard P, Hasserjian R, et al.
J Clin Oncol
. 2024 Jul;
42(27):3177-3182.
PMID: 39018505
No abstract available.
6.
Kamboj M, Bohlke K, Baptiste D, Dunleavy K, Fueger A, Jones L, et al.
J Clin Oncol
. 2024 Mar;
42(14):1699-1721.
PMID: 38498792
Purpose: To guide the vaccination of adults with solid tumors or hematologic malignancies. Methods: A systematic literature review identified systematic reviews, randomized controlled trials (RCTs), and nonrandomized studies on the...
7.
Cook M, Williams L, Dorris C, Luo Y, Makambi K, Dunleavy K
Haematologica
. 2023 Aug;
109(3):846-856.
PMID: 37646662
Primary mediastinal B-cell lymphoma (PMBCL) is a distinct clinicopathologic entity. Currently, there is a paucity of randomized prospective data to inform on optimal front-line chemoimmunotherapy (CIT) and use of consolidative...
8.
Lakhotia R, Dunleavy K, Abramson J, Link B, Powell B, Melani C, et al.
Blood Adv
. 2023 Jun;
7(18):5320-5324.
PMID: 37389844
No abstract available.
9.
Kline K, Chen W, Kallen M, Koka R, Omili D, Fan X, et al.
Hum Vaccin Immunother
. 2023 Jun;
19(2):2216116.
PMID: 37278257
Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication following kidney transplantation, and there is a critical and unmet need for PTLD treatments associated with more pronounced and durable responses....
10.
Melani C, Dowdell K, Pittaluga S, Dunleavy K, Roschewski M, Song J, et al.
Lancet Haematol
. 2023 Apr;
10(5):e346-e358.
PMID: 37011643
Background: Lymphomatoid granulomatosis is a rare Epstein-Barr virus-associated B-cell lymphoproliferative disorder with a median overall survival of less than 2 years. In this study, we hypothesised that low-grade lymphomatoid granulomatosis...